Gildea's Kite Pharma Just Acquired Interius—$350 Million Move Shakes Up Cancer Therapy

As biotechnology companies increasingly seek innovative approaches to enhance cancer treatment, strategic acquisitions are becoming a key pathway for expanding capabilities and integrating advanced therapeutic platforms. Kite Pharma, a Gilead Sciences Inc. company (NASDAQ:GILD) on Thursday agreed to acquire Interius BioTherapeutics, a privately held biotechnology company developing in vivo CAR therapeutics, for $350 million.

The acquisition complements Kite’s expertise in cell therapy by incorporating Interius’s in vivo platform.

The transaction with Interius is expected to reduce Gilead’s GAAP and non-GAAP 2025 earnings per share by approximately 23 cents to 25 cents.

Gilead Sciences raised fiscal 2025 adjusted earnings guidance from $7.70-$8.10 per share to $7.95-$8.25, compared to the consensus of $7.96.

The approach enables the generation of CAR T-cells directly within the patient’s body. It may offer a more durable and long-lasting therapeutic ...